CD33 is widely used as a marker for tumor infiltrating myeloid cells (Choi et al., 2020; Toor et al., 2021), so we collected FFPEs from 28 consecutive pairs of BC patients and performed IHC for CD74 and CD33, respectively. This evidence concerns the gene CD33 and neoplasm.